MEI Pharma Appoints New CFO and Directors
Ticker: LITS · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
MEI Pharma shakes up leadership: new CFO & 2 directors appointed.
AI Summary
MEI Pharma, Inc. announced on August 5, 2025, changes in its board and executive team. The company elected two new directors, Dr. David E. Johnson and Ms. Karen L. Smith, and appointed Mr. Michael T. Kelly as Chief Financial Officer. These changes are effective immediately and are part of the company's ongoing strategic initiatives.
Why It Matters
These executive and board changes could signal a shift in strategic direction or operational focus for MEI Pharma, potentially impacting its drug development pipeline and financial performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles and board composition can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- MEI Pharma, Inc. (company) — Registrant
- Dr. David E. Johnson (person) — Newly Elected Director
- Ms. Karen L. Smith (person) — Newly Elected Director
- Mr. Michael T. Kelly (person) — Appointed Chief Financial Officer
- August 05, 2025 (date) — Date of earliest event reported
FAQ
Who were the individuals appointed to MEI Pharma's board of directors?
Dr. David E. Johnson and Ms. Karen L. Smith were elected as new directors.
Who has been appointed as the new Chief Financial Officer of MEI Pharma?
Mr. Michael T. Kelly has been appointed as the new Chief Financial Officer.
What is the effective date of these reported changes?
The date of the earliest event reported is August 05, 2025.
What are the primary items of disclosure in this 8-K filing?
The filing concerns the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is MEI Pharma's principal executive office address?
The principal executive offices are located at 9920 Pacific Heights Blvd., Suite 150, San Diego, California, 92121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 by Dr. David E. Johnson regarding MEI Pharma, Inc. (LITS).